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Background: While studies from other coun-
tries have shown an excess mortality in diabetic
individuals when compared with the general pop-
ulation, comparable long-term data is not avail-
able for Switzerland.
Aims: To assess gender-specific cardiovascular
and non-cardiovascular mortality of patients with
type 1 and type 2 diabetes compared with the
general Swiss population between 1974 and 2005.
Design: 533 patients (225 type 1, 308 type 2
diabetes, 52.2% men) were followed for 30 years
(10349 person-years).
Results:Diabetic patients had an increased all-
cause mortality compared with the general popu-
lation (SMR [95% CI] 3.8 [3.5–4.3]). Standard-
ised mortality ratio (SMR) was higher for type 1
compared with type 2 diabetic patients (4.5 [3.8–
5.3] vs 3.5 [3.1–4.0], p = 0.032). For cardiovascu-
lar and non-cardiovascular deaths SMRs were 5.6
(95% CI 4.8–6.6) and 2.7 (2.3–3.1) and did not
differ according to type of diabetes. SMRs for all-
cause and cardiovascular mortality were signifi-
cantly higher in women compared with men in
type 1 (p <0.05 and p <0.01) and type 2 diabetes
(p <0.001 and p <0.01). In both types of diabetes,
SMRs significantly decreased during the last two
decades (p for trend 0.004 and 0.002).
Conclusions: Patients with type 1 and type 2 di-
abetes had an increased long-term mortality com-
pared with the general Swiss population. Excess
mortality was higher in type 1 compared with
type 2 diabetes and in women compared with men
for both types of diabetes, but steadily decreased
over the last two decades.
Key words: type 1 diabetes; type 2 diabetes; gender;
mortality; epidemiology
Summary
A large number of studies from various coun-
tries corroborate an increased mortality in dia-
betic patients when compared with the general
population which is mainly attributable to cardio-
vascular disease [1–3]. However, estimates for the
excess mortality due to cardiovascular causes in
diabetic patients have been shown to vary widely
across European countries: While studies from
the United Kingdom report mortality rates which
are two to 17 fold higher than in the general pop-
ulation [4, 5], a recent study from Italy revealed a
considerably lower excess mortality around 50%
[6].Moreover, few studies directly compare type 1
and type 2 diabetic individuals and results are
controversial: Several reports have suggested a
more pronounced excess mortality in patients
with type 1 compared with type 2 diabetes [5, 7–
11], whereas a recent study from Sweden reported
inverse findings [12]. Similarly, conflicting evi-
dence exists regarding the influence of gender on
the excess mortality in diabetic individuals: While
some studies have revealed a higher excess mor-
tality in diabetic women compared with their
male counterparts [4, 10, 13–20], other reports
have found a comparable risk in both genders [12,
21–23], and some have even observed inverse re-
sults [24, 25]. Such discrepancies may, at least
partly, be explained by geographical differences as
well as different underlying study populations or
potential changes in mortality risk over time.
Introduction
The study was
supported by the
Swiss National
Science Foundation
(grant number
3233B0-115212 to
Christoph Stettler).
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The present study assessed the long-term
mortality in a cohort of type 1 and type 2 diabetic
patients in Switzerland over 30 years compared
with the general population and according to
gender. Separate analyses were performed for car-
diovascular and non-cardiovascular mortality. In
addition, time changes in excess mortality of dia-
betic individuals between 1974 and 2005 were
monitored.
Materials and methods
Patients
The present study is based on the Swiss participants
of the “WHO Multinational Study of Vascular Disease in
Diabetes”, a study performed by 14 centres in 13 coun-
tries [26]. Details on the design, methods and recruitment
of the study have been described before [26–30]. In brief,
533 patients aged between 35 and 54 years were recruited
between February 1974 and May 1977 by 231 local Swiss
practitioners according to a central protocol [26, 27]. In-
formed consent was required for all patients included. Pa-
tients were classified as having type 1 diabetes if insulin
was needed for treatment within 1 year of diagnosis, oth-
erwise they were attributed type 2 diabetes. At baseline, a
standardised clinical examination was performed includ-
ing a detailed questionnaire with information on diabetes
diagnosis, the duration and treatment as well as on symp-
toms of vascular and cardiac disease, and blood samples
for biochemical measurements were taken. All analyses
were carried out in accordance with the declaration of
Helsinki and the Swiss laws regarding data safety.
Follow-up and outcome definition
The status (alive/dead) and date of death of each pa-
tient was ascertained as per January 1, 2006 based on data
obtained from population registries. In deceased patients,
the underlying cause of death was determined from a
copy of the death certificate, hospital records, post-
mortem reports (where available), and additional infor-
mation given by the treating physicians. Causes of death
were coded according to the International Classification
of Disease (ICD-9 up to January 1, 1998, and ICD-10
thereafter). Outcomes were all-cause mortality, cardiovas-
cular mortality (codes 390 to 459 and 798.1 in ICD-9,
and I00 to I99 in ICD-10), and non-cardiovascular mor-
tality (all ICD codes not covered in the category of car-
diovascular mortality). In 17 patients (9 with type 1, 8
with type 2) the cause of death could not be assigned con-
clusively and these patients were included in the analyses
of all-cause mortality exclusively.
Statistical analysis
After checking for normality, continuous baseline
characteristics between the two types of diabetes were
compared using Student’s t-test. Non normally distrib-
uted variables were transformed prior to analysis. Pear-
son’s chi-squared test was used for categorical variables.
Kaplan-Meier survival analyses were separately per-
formed in type 1 and type 2 diabetic patients. Differences
according to sex within type of diabetes were assessed
using the logrank test. Mortality rates for all-cause, car-
diovascular, and non-cardiovascular mortality were calcu-
lated for the entire cohort and separately according to
type of diabetes and sex. Since absolute mortality rates
strongly depend on age and sex, indirect age- and sex-ad-
justed standardisation of mortality rates were performed
by calculating the corresponding standardised mortality
ratios (SMRs). The expected number of deaths in the co-
hort was computed by multiplying the sex-, year- and
age-specific (in 1-year age bands for all cause mortality
and in 5-year age bands for cardiovascular and non-car-
diovascular mortality) person-years at risk within the co-
hort by corresponding mortality rates from the general
population of Switzerland. Calculations of 95% confi-
dence intervals were based on the assumption that the
number of deaths followed a Poisson distribution [31].
Sex and age-specific all-cause mortality rates for the gen-
eral Swiss population were obtained from the Human
Mortality Database (www.mortality.org) and were avail-
able up to the year 2006.The corresponding rates for car-
diovascular mortality were obtained from the Swiss Fed-
eral Statistical Office up to the year 2004. Rates for non-
cardiovascular mortality were calculated as difference
between all-cause and cardiovascular mortality rates. For
the assessment of changes in mortality over study follow-
up, annual SMRs were fitted separately for each type of
diabetes using a multivariable Poisson regression model
including sex, and linear and quadratic terms for calendar
year (centered at 1990) as covariates. In a post-hoc analy-
sis linear time-trends were assessed for observed increase
or decrease in SMR in type 1 and type 2 diabetes by re-
stricting the analyses to the year with the lowest up to the
year with the highest SMR, or vice versa, and including
calendar year as linear term as only covariate. All analyses
were performed using Stata version 10.0 (Stata Corpora-
tion, College Station, TX, USA). A p-value <0.05 was
considered statistically significant.
Results
Study characteristics
The cohort consisted of 533 patients (225
with type 1, 308 with type 2 diabetes). During fol-
low-up 35 patients (6.6%) left the country or were
lost to follow-up and were censored accordingly,
this calculated into 10349 person-years of follow
up. Baseline characteristics are summarised in
table 1.
All-cause mortality
During the study period 352 subjects died (138
with type 1, 214with type 2 diabetes) (table 2).This
translated into an all-causemortality whichwas 3.8-
fold higher compared with the general Swiss pop-
ulation, when differences in age and sex were taken
into account (SMR [95%CI] 3.8 [3.5–4.3]). Excess
mortality was higher in type 1 (SMR 4.5 [3.8–5.3])
compared with type 2 diabetes (SMR 3.5 [3.1–4.0],
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p = 0.032, table 2). In type 1 diabetes absolutemor-
tality rates tended to be higher in men than in
women: 35.5/1000 person-years (95% CI 28.1-
45.0/1000) versus 26.6/1000 person-years (21.0–
33.6/1000) (table 2) although thedifferencedidnot
reach the level of significance (p-value from log-
rank test 0.06, fig. 1a). In type 2 diabetes absolute
mortality rates were comparable betweenmen and
women: 38.3/1000 person-years (32.1–45.8/1000)
versus 35.1/1000 person-years (28.6–43.0/1000)
(table 2, fig. 1b). The SMRs for the entire follow-
up were significantly higher in women compared
with men in type 1 (SMR 5.4 [4.3–6.8] vs 3.8
[3.0–4.8], p = 0.020) and type 2 diabetes (SMR 4.7
[3.9–5.8] vs 3.0 [2.5–3.5], p <0.001) (table 2).
Cardiovascular mortality
Cardiovascular death occurred in 169 patients
(60 with type 1, 109 with type 2 diabetes). When
compared with the general population, type 1 and
type 2 diabetic patients revealed an increased risk
for cardiovascular mortality (SMR [95% CI] 5.6
[4.8–6.6], table 2) but SMRs did not significantly
differ between the two types of diabetes.Therewas
no significant genderdifference in theobserved ab-
solute mortality rates for both types of diabetes
(table 2, fig. 1c and 1d). However, women had sig-
nificantly higher cardiovascular SMRs compared
with their male counterparts in both types of dia-
betes: In type 1 diabetes SMRs were 9.5 (6.6–13.8)
versus 5.2 (3.6–7.4, p for difference 0.004); in type
2 diabetes the corresponding values were 7.2 (5.3–
9.8) versus 4.4 (3.4–5.6, p for difference 0.005)
(table 2).
Non-cardiovascular mortality
Death due to non-cardiovascular causes was
recorded in 166 patients (69 with type 1, 97 with
type 2 diabetes). Both, type 1 and type 2 diabetic
patients, showed an increased risk to die from non-
cardiovascular causes compared with the general
population (SMR [95% CI] 2.7 [2.3–3.1], table 2)
and SMRs did again not differ between type 1 and
type 2 diabetes.The absolute risk to die from non-
cardiovascular causes was comparable between
men and women within both types of diabetes
(table 2, fig. 1e and 1f). While in type 1 diabetes
SMRs formen andwomenwere comparable, there
was a strong trend towards a higher SMR in type 2
diabetic women compared with men (3.1 [2.3–4.2]
vs 2.1 [1.6–2.7], p for difference 0.052, table 2).
Time trends of mortality
In type 1 diabetes, the annual SMRs for all-
cause mortality were stable up to 1984 but con-
stantly decreased afterwards (fig. 2a, p for trend
All patients Type 1 DM Type 2 DM p for differenceType 1
vs Type 2
Demographic
Number of patients 533 225 308
Men 278 (52.2%) 104 (46.2%) 174 (56.5%) 0.019
Age (years) 45.2 (6.2) 43.0 (6.10) 46.8 (5.8) <0.001
Clinical
Diabetes duration (years) 11.9 (8.4) 15.5 (9.7) 9.2 (6.0) <0.001
Body mass index (kg/m
2
) 26.1 (5.2) 23.9 (4.2) 27.7 (5.3) <0.001
Diastolic blood pressure (mm Hg) 87.6 (11.5) 85.5 (11.2) 89.1 (11.5) <0.001
Systolic blood pressure (mm Hg) 139.0 (20.8) 136.1 (20.2) 141.1 (21.0) 0.007
Smoking status 0.75
Never 218 (40.9%) 88 (39.1%) 130 (42.2%)
Former 138 (25.9%) 59 (26.2%) 79 (25.7%)
Current 177 (33.2%) 78 (34.7%) 99 (32.1%)
Biochemical
Fasting glucose (mmol/l) 10.7 (5.3) 11.7 (6.5) 10.0 (4.1) 0.010
Total cholesterol (mmol/l) 6.4 (1.4) 6.2 (1.4) 6.6 (1.4) <0.001
Triglycerides (mmol/l) 2.0 (2.3) 1.4 (1.2) 2.4 (2.7) <0.001
Creatinine (μmol/l) 88.8 (35.2) 91.9 (43.3) 86.6 (27.4) 0.07
Micro- and macrovascular disease
Hypertension 193 (36.2%) 68 (30.2%) 125 (40.6%) 0.014
Coronary heart disease 141 (26.5%) 45 (20.0%) 96 (31.2%) 0.004
Proteinuria 120 (22.8%) 49 (21.8%) 71 (23.4%) 0.71
Retinopathy 185 (34.7%) 117 (52.0%) 68 (22.1%) <0.001
Medication
Diet alone 27 (5.1%) 0 (0.0%) 27 (9.0%) <0.001
Oral glucose-lowering drugs 215 (40.3%) 27 (12.0%) 188 (61.0%) <0.001
Insulin 315 (59.0%) 225 (100.0%) 90 (29.2%) <0.001
Lipid-lowering medication 19 (3.6%) 4 (1.8%) 15 (4.9%) 0.06
Antihypertensive medication 183 (34.3%) 55 (24.4%) 128 (24.0%) 0.07
Table 1
Baseline characteris-
tics of the study
population.
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0.004). In type 2 diabetes, there was an increase in
SMRs between 1974 and 1988 (p for trend 0.002)
and a constant decrease thereafter (p for trend
0.002, fig. 2b). Similarly, SMRs for cardiovascular
mortality steadily decreased after 1984 in type 1
(p for linear trend 0.021, fig. 2c) and after 1985 in
type 2 diabetic patients (p for linear trend 0.013,
fig. 2d). SMRs for non-cardiovascular mortality
showed a comparable decline after 1984 and
1987, in type 1 and type 2 diabetic patients, re-
spectively (p for linear trend 0.001 in both types
of diabetes, fig. 2e and 2f).
Mortality Classification Person-years Number of deaths Observed mortality rate SMR (95% CI)
Observed Expected
(per 1000 py)
All-cause Type 1
Women 2599 69 12.8 26.6 (21.0–33.6) 5.4 (4.3–6.8)
a
Men 1943 69 18.2 35.5 (28.1–45.0) 3.8 (3.0–4.8)
All 4542 138 31.0 30.4 (25.7–35.9) 4.5 (3.8–5.3)
e
Type 2
Women 2625 92 19.5 35.1 (28.6–43.0) 4.7 (3.9–5.8)
c
Men 3183 122 41.4 38.3 (32.1–45.8) 3.0 (2.5–3.5)
All 5807 214 60.8 36.9 (32.2–42.1) 3.5 (3.1–4.0)
Type 1 and 2
Women 5224 161 32.3 30.8 (26.4–36.0) 5.0 (4.3–5.8)
c
Men 5125 191 59.6 37.3 (32.3–42.9) 3.2 (2.8–3.7)
All 10349 352 91.8 34.0 (30.6–37.8) 3.8 (3.5–4.3)
Cardiovascular Type 1
Women 2554 28 2.9 11.0 (7.6–15.9) 9.5 (6.6–13.8)
b
Men 1914 30 5.8 15.7 (11.0–22.4) 5.2 (3.6–7.4)
All 4467 58 8.8 13.0 (10.0–16.8) 6.6 (5.1–8.6)
Type 2
Women 2591 40 5.6 15.4 (11.3–21.1) 7.2 (5.3–9.8)
b
Men 3139 62 14.2 19.8 (15.4–25.3) 4.4 (3.4–5.6)
All 5730 102 19.7 17.8 (14.7–21.6) 5.2 (4.3–6.3)
Type 1 and 2
Women 5145 68 8.5 13.2 (10.4–16.8) 8.0 (6.3–10.2)
c
Men 5052 92 20.0 18.2 (14.9–22.3) 4.6 (3.8–5.7)
All 10197 160 28.5 15.7 (13.4–18.3) 5.6 (4.8–6.6)
Non-cardiovascular Type 1
Women 2554 31 9.4 12.1 (8.5–17.3) 3.3 (2.3–4.7)
Men 1914 35 12.1 18.3 (13.1–25.5) 2.9 (2.1–4.0)
All 4467 66 21.5 14.8 (11.6–18.8) 3.1 (2.4–3.9)
Type 2
Women 2591 42 13.7 16.2 (12.0–21.9) 3.1 (2.3–4.2)
d
Men 3139 55 26.4 17.5 (13.5–22.8) 2.1 (1.6–2.7)
All 5730 97 40.0 16.9 (13.9–20.7) 2.4 (2.0–3.0)
Type 1 and 2
Women 5145 73 23.1 14.2 (11.3–17.9) 3.2 (2.5–4.0)
a
Men 5052 90 38.5 17.8 (14.5–21.9) 2.3 (1.9–2.9)
All 10197 163 61.6 16.0 (13.7–18.6) 2.7 (2.3–3.1)
Note that follow-up was from 1974–2005 for overall mortality and from 1974–2004 for cardiovascular and non cardiovascular mortality;
p-levels for difference between men and women:
a
<0.05,
b
<0.01,
c
<0.001,
d
0.052;
e
p for difference between type 1 and type 2
diabetes <0.05.
Table 2
Person-years, ob-
served and expected
deaths, standardised
mortality ratios
(SMR) and 95%
confidence interval.
Discussion
Based on 30 years of follow-up investigations,
this study confirms that long-term mortality was
substantially higher in diabetic patients compared
with the general Swiss population. Although this
finding is in line with previous reports from other
European countries [4–6, 8, 10, 12, 13, 15, 16, 19,
21–24, 32, 33], Northern and Southern America
[20, 34–36], New Zealand/Australia [37–39], and
Asia [14, 17, 40], SMRs in the present study may
appear comparably high. Earlier studies have re-
ported SMRs for diabetic patients ranging be-
tween 1.2 and 2.4 [6, 10, 12, 16, 32] while in the
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present analysis the overall SMR was 3.8. Such
discrepancies may either be due to differences in
absolute mortality rates in the cohort or, alterna-
tively, differences in the underlying mortality in
the reference population. It is noteworthy that
absolute mortality rates in a comparable popula-
tion of adult diabetic patients in the UK were
similar to those in the present study (about
34/1000 person-years in both studies) [10]. Con-
versely, absolute mortality rates in a cohort of
type 2 diabetic patients from Italy were reported
to be substantially higher (around 49/1000 per-
son-years compared with 37/1000 person-years in
the present study) despite lower SMRs in that
study [6]. It has been previously shown that
Switzerland has a comparably low mortality in the
general population [41, 42], which may at least
partly explain the higher SMRs in the present
analysis. This may even be more relevant with re-
spect to SMRs for cardiovascular mortality since
it has been reported that Switzerland bears one of
the lowest cardiovascular mortality rates in Eu-
rope [43]. In addition, differences in the age struc-
ture of the diverse cohorts may have influenced
SMRs, as it is known that the excess mortality of
diabetic patients becomes smaller with increasing
age [5, 9, 14, 21, 22, 37].
The results regarding differences according
to gender and type of diabetes merit closer con-
sideration: Although absolute mortality rates did
not differ between women and men, women had a
significantly higher excess mortality compared
with men for both types of diabetes and this dif-
ference was most pronounced for cardiovascular
mortality. These findings not only confirm those
of earlier reports [4, 10, 13–20] suggesting that
cardiovascular risk may disproportionately in-
crease in women with type 2 diabetes [44]. Fur-
thermore, in accordance with recent publications
[4, 13] the present study provides additional evi-
dence that similar mechanisms also may hold true
for women with type 1 diabetes. In addition to the
loss of the inherent protective endocrine status in
diabetic women [44], it has been shown that
women with diabetes and cardiovascular disease
generally have poorer control of important modi-
fiable risk factors compared with men and, for in-
stance, are offered lipid-lowering treatment less
frequently [45]. While in the present study lipid
values were similar in men and women with both
types of diabetes, women with type 2 diabetes had
a higher systolic blood pressure at baseline than
their male counterparts (data not shown). Con-
versely, a higher proportion of smokers was found
among men in both types of diabetes. While the
difference in smoking status may contribute to
the increased absolute mortality in type 1 diabetic
men, it has to remain speculative whether in type 2
diabetes the increased proportion of smokers in
men is at least partly counterbalanced by the in-
creased prevalence of hypertension in women.
So far, only few studies have directly com-
pared the mortality of patients with type 1 and
type 2 diabetes within one single study frame-
work. The finding of higher SMRs in patients
with type 1 diabetes is in accordance with several
recent studies [5, 7, 9, 11, 19, 20]. Interestingly, in-
verse findings were reported from a large Swedish
study where type 2 diabetic patients revealed
higher SMRs compared with their type 1 diabetic
counterparts [12]. A potential explanation for this
conflicting evidence could be found in the com-
parably young age of the patients in the Swedish
study, and the fact that the follow-up of these
patients was from the diagnosis of diabetes on-
wards, over a shorter period between 1983 and
1999 [12].
Excess mortality consistently declined in both
types of diabetes and both genders over the past
two decades. A similar decline in SMRs has also
been reported in a recent cohort study in Sweden
over 20 years of follow-up [9] as well as in a report
from the Danish National Diabetes Register, al-
though the latter did not differentiate between
type 1 and type 2 diabetes [21]. In the present
study, the changes in SMRs over time are likely to
be due to several reasons: Firstly, a slight excess
mortality due to comparably young individuals
was observed in the first years which could poten-
tially be responsible for the initial increase in
Figure 1
Kaplan-Meier estimation of survival probabilities according to type of diabetes and
sex for all-cause mortality (Panels a and b), cardiovascular mortality (Panels c and d),
and non-cardiovascular mortality (Panels e and f).
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SMRs, especially in type 2 diabetes. Secondly, a
selection of healthier individuals over the study
time cannot fully be ruled out. However, a careful
assessment of expected and observed mortality
rates in age-specific strata over time made a rele-
vant selection bias unlikely (data available on re-
quest). As a consequence, it is likely that the ob-
served decline in SMRs over the last two decades
in both types of diabetes reflects a true effect of
improved treatment guidelines and strategies.
While the results of the large Diabetes Control
and Complications Trial (DCCT) were made
public only in 1993 [46], a number of randomised
controlled trials already suggested a beneficial
effect of intensified glycaemic control in type 1
diabetes in the previous years [47–52]. In type 2
diabetes, the results of the University Group Dia-
betes Program (UGDP) study [53], though con-
troversial, may have influenced therapeutic strate-
gies before the publication of the landmark Veter-
ans Affairs (VA) trial and the United Kingdom
Prospective Study (UKPDS) [54, 55]. In addition,
treatment options to tackle concomitant cardio-
vascular risk factors (for example statins or anti-
hypertensive drugs) have steadily increased over
the last years and environmental factors (dietary
changes for example) may have further reduced
excess mortality [56–58].
The strength of the present study lies in a
comparably long follow-up of a well-defined co-
hort [26, 27] including both types of diabetes.The
study had a low drop-out rate and evaluated pre-
specified endpoints. Still, there are some limita-
tions to be acknowledged: Firstly, the design of
the study did not allow to repetitively collect in-
formation on specific treatment modalities or
clinical or biochemical parameters (HbA1c for ex-
ample) during follow-up.Therefore, the interpre-
tation of the observed time trends in mortality has
to remain limited and to some extent speculative,
despite careful assessment to avoid potential bias.
Secondly, the absolute number of patients in the
current study was comparably small and a careful
follow-up may only partly offset this shortcom-
ing. In addition, despite the fact that recruitment
was done by local practitioners in various regions
of Switzerland and according to an internation-
ally approved central protocol, a potential selec-
tion bias can not be fully ruled out. Thirdly, the
underlying cause of death was generally deter-
mined from a copy of the death certificate, which
is a comparatively unreliable source of informa-
tion. Despite all efforts to collect comprehensive
data from hospital records, post-mortem reports,
and by the treating physicians, the cause of death
may have been misclassified in some cases. Finally,
the general population of Switzerland (including
diabetic and non-diabetic individuals) was used as
the reference to calculate SMRs and this may
have resulted in underestimation of the excess risk
for diabetic patients.
In summary, the present long-term follow-up
study revealed an increased mortality of diabetic
patients compared with the general Swiss popula-
tion. Excess mortality was highest for cardiovas-
cular disease in both types of diabetes. Of con-
cern, women with both types of diabetes showed a
significantly higher excess mortality compared
with men for both types of diabetes and this was
essentially attributable to an excess in cardiovas-
cular mortality. The constant decline of excess
mortality in both types of diabetes and in both
genders over the past two decades indicates a ben-
eficial impact of improved treatment strategies.
However, the present results also suggest that fur-
ther efforts to outweigh persistent gender-specific
differences in diabetic patients may still be re-
quired.
We are indebted to the study participants, their rela-
tives as well as their treating physicians and staff for their
participation, help and support throughout the study.We
are also grateful for the support we received from the
Federal Office of Statistics, Neuchâtel (C. Junker and
E. Wüest) and the various community based population
registries throughout the country. We thank Prof.
A.Teuscher, E. Hurni, Dr. P.P. Studer, and Dr. H. Schnell
for help with the collection of the baseline data.
Figure 2
Fitted SMRs according to type of diabetes and sex for all-cause mortality (Panels a and
b), cardiovascular mortality (Panels c and d), and non-cardiovascular mortality (Panels
e and f). SMRs were modelled using a Poisson-regression model including sex and the
calendar year (centered at 1990) as linear and quadratic term.
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